News

Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial

Major operational milestone achieved with interim data on track…

Hansa Biopharma appoints Fredrik Röök as VP Business Development

Lund, Sweden, 10 June 2026. Hansa Biopharma AB, “Hansa” (Nasdaq…

Sofinnova Partners launches collaboration with AWS to scale AI across life sciences innovation

Sofinnova combines its sector expertise with AWS’s AI and…

DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration

Dalton is a drug discovery platform integrating agentic AI,…

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

Oversubscribed Series B financing co-led by new investors…

Hansa Biopharma participating in Jefferies Global Healthcare Conference in New York

Lund, Sweden, June 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq…

Hansa Biopharma’s CEO Renée Aguiar-Lucander named one of Sweden’s Most Influential Business Women of 2026

Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq…

ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics

Commercial-scale production of Kaleido consumables begins…

Poolbeg Pharma plc – pre-IND meeting with the FDA for POLB 001

FDA feedback supports Poolbeg's proposed development pathway…

Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis

Results support progression of EMERALD clinical trial of Resolution’s…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.